THERAPEUTIC RESULTS WITH CEFTIZOXIME IN COMPLICATED URINARY TRACT INFECTION

Abstract

A clinical trial of ceftizoxime, a new injectable cephalosporin derivative, was conducted to assess itseffectiveness and safety in the treatment of urinary tract infections. Five patients with chronic pyelonephritis, including 2 cases of acute exacerbation, and 10 patients with chronic complicated cystitis received the drug, 0.5-2g twice daily for 5 days by i. V. drip infusion. By the criteria for drug efficacy evaluation in urinary tract infections, the therapeutic response was excellent in 1 case, good in 10 and poor in 4; hence an overall clinical effectiveness rate of 73. 3%. No subjective or objective adverse reactions were observed in any of the patients treated.